Claims for Patent: 8,927,607

Summary for Patent: 8,927,607

Title:	Methods of colchicine administration
Abstract:	The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
Inventor(s):	Ducharme; Murray (St Laurent, CA)
Assignee:	Hikma Pharmaceuticals LLC (Amman, JO)
Application Number:	13/973,897
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,927,607
Patent Claims:	1. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behcet's disease, with colchicine while concomitantly administering a second drug that is an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4) but is not an inhibitor of P-glycoprotein 1 (P-gp), wherein the second drug is voriconazole, fluconazole or cimetidine wherein the method comprises: a) administering to the patient a therapeutically effective fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering the second drug; b) after step (a), administering to the patient one or more therapeutically effective doses of the second drug; and c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction. 2. The method of claim 1, wherein the second drug is voriconazole administered at a dose of from 200 mg/day to 400 mg/day. 3. The method of claim 1, wherein the second drug is fluconazole administered at a dose of from 200 mg/day to 400 mg/day. 4. The method of claim 1, wherein the second drug is cimetidine administered at a dose of from 800 mg/day to 1,600 mg/day. 5. The method of claim 1, wherein said fixed maintenance dose of colchicine is 0.6 mg/day. 6. The method of claim 1, wherein said fixed maintenance dose of colchicine is 1.2 mg/day. 7. The method of claim 1, wherein the inflammatory disorder is chronic gout. 8. The method of claim 1, wherein said plurality of days comprises at least 7 days. 9. The method of claim 1, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, said inflammatory disorder is chronic gout, and said second drug is voriconazole. 10. The method of claim 1, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, said inflammatory disorder is chronic gout, and said second drug is voriconazole administered at a dose of from 200 mg/day to 400 mg/day. 11. The method of claim 1, wherein said fixed maintenance dose of colchicine is 1.2 mg/day, said inflammatory disorder is chronic gout, and said second drug is voriconazole. 12. The method of claim 1, wherein said fixed maintenance dose of colchicine is 1.2 mg/day, said inflammatory disorder is chronic gout, and said second drug is voriconazole administered at a dose of from 200 mg/day to 400 mg/day. 13. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behcet's disease, by administering colchicine while concomitantly administering an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4) which is not an inhibitor of P-glycoprotein 1 (P-gp), wherein the inhibitor of cytochrome P450 3A4 isoenzyme (CYP3A4) is voriconazole, fluconazole or cimetidine, wherein the method comprises: a) administering to the patient a plurality of therapeutically effective doses of the inhibitor of cytochrome P450 3A4 isoenzyme (CYP3A4) for a plurality of days without administering colchicine; b) after step (a), administering to the patient one or more fixed maintenance doses of colchicine in an amount from about 0.6 to about 1.2 mg/day; c) concomitantly with step (b) administering to the patient a plurality of effective doses of the inhibitor of cytochrome P450 3A4 isoenzyme (CYP3A4); d) after step (c), discontinuing administration of the inhibitor of cytochrome P450 3A4 isoenzyme (CYP3A4) and continuing to administer the fixed maintenance dose of colchicine administered in step (b) without dose adjustment. 14. The method of claim 13, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, said inflammatory disorder is chronic gout, and said inhibitor of cytochrome p450 3A4 isozyme (CYP3A4) is voriconazole. 15. The method of claim 13, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, said inflammatory disorder is chronic gout, and said inhibitor of cytochrome p450 3A4 isozyme (CYP3A4) is voriconazole administered at a dose of from 200 mg/day to 400 mg/day. 16. The method of claim 13, wherein said fixed maintenance dose of colchicine is 1.2 mg/day, said inflammatory disorder is chronic gout, and said inhibitor of cytochrome p450 3A4 isozyme (CYP3A4) is voriconazole. 17. The method of claim 13, wherein said fixed maintenance dose of colchicine is 1.2 mg/day, said inflammatory disorder is chronic gout, and said inhibitor of cytochrome p450 3A4 isozyme (CYP3A4) is voriconazole administered at a dose of from 200 mg/day to 400 mg/day.